Prevalence in Hypertension

IN THE CATALYST STUDY, AMONG PATIENTS WITH DIFFICULT-TO-CONTROL TYPE 2 DIABETES (T2D) TAKING 3+ HYPERTENSION MEDICATIONS37% were diagnosed with endogenous hypercortisolism1

Thirty-seven percent (eighty-six out of two-hundred-thirty-five).

More than 1 in 3 patients (37%) with difficult-to-control T2D who were taking ≥3 hypertension medications had endogenous hypercortisolism1

Endogenous hypercortisolism was defined as:

  • Post 1-mg DST cortisol >1.8 μg/dL

  • Confirmed AM dexamethasone level ≥140 ng/dL

Post 1-mg DST cortisol >1.8 μg/dL is indicative of hypercortisolism. An AM serum dexamethasone level ≥140 ng/dL is sufficient to suppress cortisol in healthy individuals and confirms the test was performed correctly.

CATALYST was the largest US prospective clinical trial ever conducted to investigate the prevalence of endogenous hypercortisolism.2

Difficult-to-control T2D with diagnosis ≥1 year prior was defined as patients having an HbA1c of 7.5% - 11.5% and taking2:

  • ≥3 T2D medications OR

  • Insulin and other T2D medication(s) OR

  • ≥2 T2D medications AND

    • The presence of ≥1 microvascular or macrovascular complications AND/OR

    • Concomitant hypertension requiring ≥2 hypertension medications

STUDY DETAILS

Patients with hypercortisolism often do not present with obvious physical features3

<0.1%

OF PATIENTS DEVELOPED OBVIOUS PHYSICAL FEATURES

In a systematic review and meta-analysis of 32 studies reporting outcomes from 4121 patients, less than 0.1% of patients with autonomous cortisol secretion developed these features after >4 years of follow-up3

Explore the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes

UNCOVER PREVALENCE

Learn about the risks of hypercortisolism

VIEW DATA

Discuss the recent prevalence data with a Corcept representative

CONTACT A REP

References

1. Buse JB, Kahn SE, Aroda VR, et al. Diabetes Care. 2025;48(00):1-9. doi:10.2337/dc24-2841 2. DeFronzo RA, Auchus RJ, Bancos I, et al. BMJ Open. 2024;14(7):e081121. doi:10.1136/bmjopen-2023-081121 3. Elhassan YS, Alahdab F, Prete A, et al. Ann Intern Med. 2019;171(2):107-116. doi:10.7326/M18-3630 4. Petramala L, Olmati F, Concistrè A, et al. Endocrine. 2020;70(1):150-163. doi:10.1007/s12020-020-02297-2 5. Nieman LK, Biller BM, Findling JW, et al. J Clin Endocrinol Metab. 2008;93(5):1526-1540. doi:10.1210/jc.2008-0125 6. Ciftel S, Mercantepe F. Cureus. 2023;15(11):e48383. doi:10.7759/cureus.48383 7. Giovanelli L, Aresta C, Favero V, et al. J Endocrinol Invest. 2021;44(8):1581-1596. doi:10.1007/s40618-020-01484-2 8. Aresta C, Soranna D, Giovanelli L, et al. Endocr Pract. 2021;27(12):1216-1224. doi:10.1016/j.eprac.2021.07.014